China Medical System (00867.HK): Marketing Authorization Application for Innovative Drug Ruxolitinib Phosphate Cream Approved in Singapore

Zhitong Finance APP News, China Medical System (00867.HK) announced that its subsidiary RxilientMedical obtained approval from the Health Sciences Authority of Singapore (HSA) on November 3, 2026 for the New Drug Application (NDA) of Ruxolitinib Phosphate Cream (the "Product" or "Lumirix") (vitiligo indication). The product is indicated for the treatment of nonsegmental vitiligo with facial involvement in adolescent and adult patients aged 12 years and older. It is Singapore's first and only topical prescription drug that directly targets the pathophysiological mechanism of vitiligo, addressing long-unmet clinical needs.